Doctor Groups Break With CDC to Issue Independent Vaccine Guidance
Medical professional endorsements bypass federal approval bottlenecks, preserving private-sector vaccine demand by anchoring commercial reimbursement to independent clinical consensus rather than shifting CDC policy.
U.S. medical organizations issued independent vaccine guidelines for the upcoming respiratory illness season, breaking from the CDC amid an ongoing leadership overhaul at the federal agency. Professional groups representing pediatricians, family physicians, and obstetricians released the recommendations jointly with the University of Minnesota’s Vaccine Integrity Project. The split follows the June 2025 dismissal of the CDC Advisory Committee on Immunization Practices by health secretary Robert F. Kennedy Jr. and its subsequent replacement by vaccine skeptics. The CDC stated that flu recommendations from last July remain in effect for the 2026-2027 season, while federal programs such as Vaccines for Children will continue to supply free immunizations. The newly issued independent largely mirrors pre-upheaval federal recommendations, though the American College of Obstetricians and Gynecologists extended its RSV vaccination window for pregnant individuals through March 1.
FTC Approves Final Consent Decree for Ascension/AmSurg Deal With Divestitures
Forcing surgery center divestitures into local specialist practices creates instant, well-capitalized regional competitors that cap pricing power for health systems expanding their outpatient footprint.
The Federal Trade Commission finalized a consent order requiring Ascension Health Alliance to divest seven ambulatory surgery centers to complete its $3.9 billion of AmSurg. The final order settles allegations that combining the two outpatient surgical providers would substantially lessen competition across the Nashville, Panama City, Tulsa, Waco, and Wichita metropolitan areas. Under the terms of the decree, six of the divested centers go to SC Affiliates, while Florida Gastroenterology Center assumes full ownership of the seventh facility in Panama City. The agreement also imposes a ten-year prior notice obligation on Ascension for any future surgery center acquisitions in the affected markets, alongside standard transition assistance and maintenance provisions. The enforcement action stems from a June 2026 complaint alleging the would drive up prices and reduce care quality for gastroenterology, ophthalmology, and orthopedist procedures.
Ultragenyx Angelman syndrome drug fails late-stage trial
When placebo controls invalidate early rare-disease signals, commercial biotechs lose the primary pipeline bridge required to turn current ultra-rare revenues into company-wide profitability.
statnews.com reports that Ultragenyx announced Wednesday its experimental Angelman syndrome therapy, GTX-102, showed no benefit over a sham treatment in a . The rare disease causes severe intellectual disabilities and developmental delays, and the drug had previously shown powerful results in early studies. Investors had been banking on the therapy as the company's path to profitability. The trial failure deals a significant blow to the biotech firm despite its of other approved medicines for ultra-rare conditions.
American Healthcare REIT Partners With Kensington After $572 Million Portfolio Deal
Structuring the transaction as a sale-leaseback allows American Healthcare REIT to acquire high-barrier urban senior housing assets while keeping Kensington's operational team in place.
American Healthcare has acquired six luxury senior housing communities from Kensington Senior Living for $572 million. The initial six-property purchase includes 464 units across the Los Angeles, San Francisco Bay Area, Washington, D.C., and New York metropolitan markets. The transaction is part of a broader eight-community totaling 745 units and $873 million in total planned investment. Kensington will remain the operator of the properties under a newly formed long-term strategic partnership. The remaining two communities are under definitive purchase agreements and are expected to close in the fourth quarter of this year.
Kensington Portfolio Acquisition Value ($M)
The initial six communities represent $572 million of an $873 million portfolio.
Novartis and Bristol Myers Pause Autoimmune CAR-T Trials Due to Safety Concerns
Linking accelerated manufacturing to systemic inflammation directly undermines the economic thesis that faster production cycles can make CAR-T therapies viable for mass autoimmune markets.
Novartis and Bristol Myers Squibb have halted multiple testing cell therapies in autoimmune diseases following severe inflammatory side effects. Novartis paused development of its personalized CAR-T treatment, rap-cel, on Aug. 24 after detecting three cases of immune effector cell-associated hemophagocytic syndrome. The hold affects studies evaluating rap-cel across multiple indications including lupus, myasthenia gravis, and multiple sclerosis. Bristol Myers voluntarily paused enrollment in trials for its own CAR-T therapy, zola-cel, after observing transient inflammatory events during routine safety surveillance. Both therapies rely on rapid manufacturing platforms designed to speed up production compared to older treatments. William Blair analyst Sami Corwin noted that this accelerated manufacturing process could be driving increased cell expansion and the resulting toxicities. While both companies have paused their autoimmune work, their cancer programs involving the respective therapies remain active.
External co-funding for secondary indications shifts trial risk away from core R&D budgets, allowing early-stage immunology assets to advance into expensive late-stage testing with less balance-sheet strain.
Teva Pharmaceutical Industries reported that its experimental anti-interleukin-15 antibody, TEV '408, met the primary endpoint in a phase 2a trial for celiac disease. In the trial of 50 adults, a single injection significantly reduced intestinal damage compared to placebo after participants ate gluten daily for six weeks. Teva reported no safety signals associated with the drug. The company must conduct more dose-ranging and data analysis before starting a . Royalty Pharma previously agreed to provide up to $500 million to help fund development for a separate vitiligo in exchange for a share of future sales.
Eli Lilly to Acquire Merida Biosciences for $2.88 Billion
Selective antibody degradation shifts immunology M&A from broad immunosuppression toward targeted clearance platforms, forcing legacy symptom-blocking therapies to defend their market share against curative mechanisms.
Eli Lilly has agreed to acquire privately held Merida Biosciences for up to $2.88 billion in an all-cash deal spanning upfront payments and undisclosed milestones. The transaction gives Lilly control of an antibody-engineering platform designed to degrade pathogenic autoantibodies rather than broadly suppressing the immune system. Merida's lead program, MER511, is currently in a Phase 1 for Graves' disease and thyroid eye disease. Lilly expects the to close in the fourth quarter of 2026, pending customary regulatory clearance.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.